Предупреждение диабетического поражения почек: фокус на антигипертензивные препараты

1. Platinga LC, Crews DC, Coresh J et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673–82.
2. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. и др. Диабетическая нефропатия: факторы риска быстрого прогрессирования почечной недостаточности. Тер. архив. 1999; 6: 38–41.
3. Matsushita K, van der Velde M, Astor BC et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073–81.
4. EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with normotensive diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 347: 1787–92.
5. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
6. Perkovic LvJ, Foote CV, Craig ME et al. Antihypertensive agents for preventing diabetic kidney disease (review). Cochrane Library 2012: Issue 12.
7. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (The ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
8. Haller H, Ito S, Izzo JL et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. 
N Engl J Med 2011; 364: 907–17.
9. Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11–20.
10. Savarese G, Constanzo P, Clelend JGF et al. A meta-analysis reporting effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. JACC 2013; 61 (2): 131–42.
11. HOPE Study Group. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253–9.
12. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
13. Makino H, Haneda M, Babazono T et al. INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30 (6): 1577–8.
14. Menne J, Izzo JL, Ito S et al. ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30 (4): 811–8.
15. Tobe SW, Clase CM, Gao P et al. ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people with high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123 (10): 1098–107.
16. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes mellitus. N Engl J Med 2004; 351 (19): 1941–51.
17. Ritz E, Orth SR. Nephropathy in type 2 diabetes mellitus. N Engl J Med 1999; 341 (15): 1127–33.
18. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012; 30 (3): e156–e166.

В.В.Фомин, А.А.Свистунов

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ